BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34166375)

  • 1. Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma.
    Takashima Y; Kawaguchi A; Fukai J; Iwadate Y; Kajiwara K; Hondoh H; Yamanaka R
    PLoS One; 2021; 16(6):e0251272. PubMed ID: 34166375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.
    Takashima Y; Hamano M; Fukai J; Iwadate Y; Kajiwara K; Kobayashi T; Hondoh H; Yamanaka R
    Sci Rep; 2020 May; 10(1):8435. PubMed ID: 32439996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal expression of the immune response genes CXCR3 and IFI44L as module hubs are associated with patient survivals in primary central nervous system lymphoma.
    Takashima Y; Hamano M; Yoshii K; Hayano A; Fukai J; Iwadate Y; Kajiwara K; Hondoh H; Yamanaka R
    Int J Clin Oncol; 2023 Mar; 28(3):468-481. PubMed ID: 36607476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma.
    Takashima Y; Kawaguchi A; Iwadate Y; Hondoh H; Fukai J; Kajiwara K; Hayano A; Yamanaka R
    PLoS One; 2019; 14(1):e0210400. PubMed ID: 30615673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
    Takashima Y; Kawaguchi A; Iwadate Y; Hondoh H; Fukai J; Kajiwara K; Hayano A; Yamanaka R
    PLoS One; 2020; 15(2):e0229577. PubMed ID: 32101576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.
    Takashima Y; Kawaguchi A; Sato R; Yoshida K; Hayano A; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Nakano M; Ogawa S; Tashiro K; Yamanaka R
    Sci Rep; 2019 Jul; 9(1):10004. PubMed ID: 31292525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.
    Barakat M; Albitar M; Whitney R; Abdulhaq H
    Cancer Treat Res Commun; 2021; 27():100310. PubMed ID: 33581493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma.
    Liu J; Wang Y; Sun X; Ji N; Sun S; Wang Y; Liu F; Cui Q; Wang C; Liu Y
    Oncol Rep; 2017 Feb; 37(2):887-894. PubMed ID: 27959415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
    Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
    Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
    Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
    Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of immunoglobulin H gene rearrangement by polymerase chain reaction in primary central nervous system lymphoma.
    Kros JM; Bagdi EK; Zheng P; Hop WC; Driesse MJ; Krenacs L; Dinjens WN
    J Neurosurg; 2002 Dec; 97(6):1390-6. PubMed ID: 12507138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma.
    Hilal T; Maguire A; Kosiorek HE; Rimsza LM; Rosenthal AC
    Leuk Lymphoma; 2019 Dec; 60(14):3581-3583. PubMed ID: 31246148
    [No Abstract]   [Full Text] [Related]  

  • 13. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
    Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
    J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma.
    He J; Wu J; Jiao Y; Rodriguez FJ; Blakeley JO; Kinzler KW; Papadopoulos N; Vogelstein B; Holdhoff M
    J Neurooncol; 2013 Sep; 114(3):275-9. PubMed ID: 23828278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
    Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
    Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
    [No Abstract]   [Full Text] [Related]  

  • 16. Insights into the biology of primary central nervous system lymphoma.
    Mrugala MM; Rubenstein JL; Ponzoni M; Batchelor TT
    Curr Oncol Rep; 2009 Jan; 11(1):73-80. PubMed ID: 19080745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.
    Bruno A; Labreche K; Daniau M; Boisselier B; Gauchotte G; Royer-Perron L; Rahimian A; Lemoine F; de la Grange P; Guégan J; Bielle F; Polivka M; Adam C; Meyronet D; Figarella-Branger D; Villa C; Chrétien F; Eimer S; Davi F; Rousseau A; Houillier C; Soussain C; Mokhtari K; Hoang-Xuan K; Alentorn A
    Neuro Oncol; 2018 Jul; 20(8):1092-1100. PubMed ID: 29432597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in primary central nervous system lymphoma (PCNSL).
    Takeuchi H; Matsuda K; Kitai R; Sato K; Kubota T
    J Neurooncol; 2007 Sep; 84(2):141-5. PubMed ID: 17406788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of genomic alterations in primary central nervous system lymphomas.
    Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
    J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperglycemia is associated with poor survival in primary central nervous system lymphoma patients.
    Debata A; Yoshida K; Ujifuku K; Yasui H; Kamada K; Niino D; Matsuo T
    Tumori; 2017 May; 103(3):272-278. PubMed ID: 28058711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.